All In Biotech

Drug Trial Radar · NCT06900543

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Mar 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.

Conditions

  • Unresectable Hepatocellular Carcinoma

Interventions

  • NRT6003 InjectionDrug

    Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.

  • cTACEDrug

    Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Progression (TTP)Time frame: Through study completion, at least 18 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • The First Hospital Affiliated to the Army Medical University

    Chongqing, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Xi'an International Medical Center Hospital

    Xi’an, Shanxi, China

  • West China Hospital

    Chengdu, Sichuan, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.